摘要
目的:确定硒酸酯多糖对化疗患者免疫功能的调节作用。方法:采用随机分组双盲临床试验,观察化疗患者口服硒酸酯多糖(κ- 硒卡拉胶)(治疗组)与安慰剂(对照组)对免疫功能的影响。结果:治疗组患者T4 细胞百分比从疗前279±74 升至381 ±108( P<005),T4/T8 比值从092±023 升至127±050( P< 001) ,而对照组T4 、T8 细胞及T4/T8 比值无明显变化。治疗组患者巨噬细胞吞噬率从245 ±194 升至319 ±153( P< 001) ,对照组则从254 ±154 降至216±223( P< 001) 。两组患者NK 细胞活性、Ig 含量、近期疗效及毒性反应似无显著差异。结论:硒酸酯多糖是一种安全有效的免疫调节剂。
To evaluate the clinical usefulness of κ-selenocarrageenan (Se-C) in immunomodulation, a total of 42 patients were enrolled in a randomized, double-blind, placebo-controlled phase II clinical trial Of them 26 patients were given oral administration of 100mg Se-C capsule and 16 patients were given oral administration of placebo once a day for two consecutive weeks and was repeatedly administered in the subsequent cycle in the same manner Immune functions were assessed after six weeks The results showed that the percentage of T 4 cells was increased from 27 9±7 4 to 38 1±10 8 ( P <0 05) and T 4/T 8 ratio was increased from 0 92±0 23 to 1 27±0 50 ( P <0 01) in treatment group Percentage of phagocytosis of macrophages was increased from 24 5±19 4 to 31 9±15 3 ( P <0 01) in treatment group and decreased from 25 4±15 4 to 21 6±22 3 ( P <0 01) in control group NK cell activity, Ig contents, response rate and adverse effects were comparable in both groups Conclusion: Se-C is an effective immunomodulatory agent
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1999年第9期678-680,共3页
Chinese Journal of Clinical Oncology